Phase I/II trial of dose-reduced capecitabine in elderly patients with advanced colorectal cancer.

Vincent, M D; Breadner, D; Cripps, M C; Jonker, D J; Klimo, P; Biagi, J J; Lam, W; O'Connell, A; Whiston, F; Stitt, L; Welch, S A

Vincent, M D; Breadner, D; Cripps, M C; Jonker, D J; Klimo, P; Biagi, J J; Lam, W; O'Connell, A; Whiston, F; Stitt, L; Welch, S A.

Afiliación

Vincent MD; London Regional Cancer Program, London, ON.
Breadner D; Schulich School of Medicine and Dentistry, London, ON.
Cripps MC; London Regional Cancer Program, London, ON.
Jonker DJ; Schulich School of Medicine and Dentistry, London, ON.
Klimo P; Department of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON.
Biagi JJ; Department of Medical Oncology, The Ottawa Hospital Cancer Centre, Ottawa, ON.
Lam W; Medical Oncology, Lions Gate Hospital, North Vancouver, BC.
O'Connell A; Department of Oncology, Queen's University, Kingston, ON.
Whiston F; Burnaby Hospital Cancer Centre, Burnaby, BC.
Stitt L; London Regional Cancer Program, London, ON.
Welch SA; London Regional Cancer Program, London, ON.

Curr Oncol ; 24(4): e261-e268, 2017 Aug.

Article en En | MEDLINE | ID: mdl-28874896

Palabras clave

Colorectal cancer, advanced; capecitabine; elderly patients; frail patients; sequential monotherapy

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Curr Oncol Año: 2017 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google